Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
April 11, 2017 – The FDA announced the approval of Neurocrine Biosciences’ Ingrezza (valbenazine), for the treatment of adults with tardive dyskinesia (TD).
Return to publications